Oncology & Cancer

New study could enhance treatments for drug-resistant melanoma

Melanoma is the deadliest form of skin cancer, killing more than 8,000 in the U.S. each year. Approximately 40 percent of advanced melanoma tumors are driven to grow by the presence of mutations in a gene known as the BRAF ...

Oncology & Cancer

Studying resistance to therapy in BRAF-mutated brain tumors

Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including ...

Oncology & Cancer

New biomarker may help guide treatment of melanoma patients

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC ...

page 5 from 12